• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
april@madhedgefundtrader.com

AI And Lower Employee Wages

Tech Letter

Students hoping to become bankers shouldn’t study finance, they should dive into programming.

This is the big takeaway from how investment banks are run these days.

Gone are the moments when finance degrees were the hottest commodity, now it is all about generative AI.

Artificial intelligence (AI) could replace the equivalent of 300 million full-time jobs, a report by investment bank Goldman Sachs says.

It could replace a quarter of work tasks in the US and Europe but may also mean new jobs and a productivity boom.

And it could eventually increase the total annual value of goods and services produced globally by 7%.

Generative AI, able to create content indistinguishable from human work, is "a major advancement", the report says.

Silicon Valley is keen to promote investment in AI in not only the United States but in a way that will ultimately drive productivity gains across the global economy.

The report notes AI's impact will vary across different sectors - 46% of tasks in administrative and 44% in legal professions could be automated but only 6% in construction and 4% in maintenance, it says.

Journalists will therefore face more competition, which would drive down wages unless we see a very significant increase in the demand for such work.

Consider the introduction of GPS technology and platforms like Uber (UBER). Suddenly, knowing all the streets in London had much less value - and so incumbent drivers experienced large wage cuts in response, of around 10% according to our research.

The result was lower wages, not fewer drivers.

Over the next few years, generative AI is likely to have similar effects on a broader set of creative tasks.

According to research cited by the report, 60% of workers are in occupations that did not exist in 1940.

However, other research suggests technological change since the 1980s has displaced workers faster than it has created jobs.

Nobody understands how the technology will evolve or how firms will integrate it into how they work.

Lower wages and higher output are a perfect recipe for higher technology share prices and that is exactly what we will get.

Currently, we are experiencing a mild pullback from the AI mania, but that is simply because it got too far ahead of its skis.

I am quite disappointed in the price action in a stock like Tesla (TSLA) which announced a major cut to its global workforce to trim costs.

The staff cut of 10% could result in exactly what I mentioned more output for less pay, but in terms of hiring more workers, they have decided to force fewer workers to do more.

This type of management behavior doesn’t usually pan out well, because it usually leads to an employee rebellion and cratering employee satisfaction.

They will certainly be a major investor in AI chips to outfit their EV cars, but they have signaled to investors that they are experiencing trouble reaching that “2nd wave” of incremental buyers for their car.

Tech as a whole is not in trouble, but individual companies will find an imbalance treatment to their stock.

The AI pixie dust might have leveled off in the short term, and the broader tech market is being dragged down by a confluence of headwinds like spiking interest rates, geopolitical strive, beaten-up consumers, and diminishing addressable market revenue.

I do believe in the AI hype, but these trends don’t go up in a straight line and need time to digest which often results in short-term pullbacks.

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-04-17 14:02:152024-04-17 16:14:42AI And Lower Employee Wages
april@madhedgefundtrader.com

April 17, 2024

Jacque's Post

 

(INVESTORS INTERPRETATION OF DATA MOVES THE MARKET – OPPORTUNITIES ARE SETTING UP)

April 17, 2024

 

Hello everyone,

The stock market correction.  What’s it all about?

Lingering inflation concerns.  We know it will be higher for longer.  Fed will react to economic data eventually. 

Rising Treasury yields. 

Turmoil in the Middle East.

Healthy correction in a bull market.

Corrections are common in bull markets and the speed of recovery is relatively fast. There have been 24 corrections since World War II with an average decline of 13.9% and lasting about four months, and it took the S&P 500 four months to recover all that was lost in the decline, according to Sam Stovall, chief investment strategist at CFRA Research.

A 10% decline is defined as a correction in one of the major stock indexes.  A 20% or greater decline indicates we have moved into bear market territory. 

CFRA Research shows us that if we go back to 1990, the market fell an average of 14.7% in a correction and was able to recoup the losses in the correction in only three months.

 

 

So, for long-term investors – it’s better to hang on than to jump.

With the S&P 500 now sitting below its 50-day moving average, we may have further downside to go.  We will probably see relief rallies, but while the S&P 500 is below 5114, the risk is to the downside.

The way to look at this correction is as a healthy consolidation after a very strong return in the first quarter.  It doesn’t change the fundamentals.  We should continue to rally into year-end, but it won’t be a straight line.

 

 

So, where should we be looking for opportunities?

There will be continued demand for AI and AI-related technologies.  Therefore, we should have our focus on AI software and semiconductor companies.  Additionally, let’s not forget global commodity producers and miners, particularly those related to copper.

Miners (Copper) (FCX)

AI – Nvidia (NVDA), Microsoft (MSFT), Advanced Micro Devices (AMD), Amazon (AMZN),

Taiwan Semiconductor Manufacturing Co (TSM), Applied Materials (AMAT), Dell Technologies (DELL), Meta Platforms (META)

Miners (BHP), (RIO), (CVX)

Of course, this is not a complete list of every company in the categories I’ve mentioned.  But it’s a good place to start.

 

 

This is a very sad sign of the times.  In just about every shop and place of business I go into today, these signs are present.

 

 

Cheers,

Jacquie

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-04-17 12:00:332024-04-17 11:28:58April 17, 2024
april@madhedgefundtrader.com

April 17, 2024

Diary, Newsletter, Summary

Global Market Comments
April 17, 2024
Fiat Lux

 

Featured Trade:

(THE LAZY MAN’S GUIDE TO TRADING),
(ROM), (UXI), (BIB), (UYG),
(THE NEXT THING FOR THE FED TO BUY IS GOLD)
(GLD), (GOLD), (GDX), (NEM)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-04-17 09:06:442024-04-17 10:42:20April 17, 2024
april@madhedgefundtrader.com

April 16, 2024

Biotech Letter

Mad Hedge Biotech and Healthcare Letter
April 16, 2024
Fiat Lux

 

Featured Trade:

(IS THIS BIOTECH BULL RUN OUT OF STEAM?)

(VRTX), (CRSP)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-04-16 12:02:462024-04-16 11:27:06April 16, 2024
april@madhedgefundtrader.com

Is This Biotech Bull Run Out Of Steam?

Biotech Letter

Vertex Pharmaceuticals (VRTX) has been crushing it. They're a powerhouse in the healthcare game, no doubt.

But with that stock price shooting for the moon and a $100 billion valuation, it's got me asking: Is this ride getting a little too rich for our blood? Is it time to cash out and look for greener pastures, or is there still some juice left in Vertex's tank?

Let's take a look at why the Vertex bulls are so pumped.

The company's a giant in cystic fibrosis – no argument there. Their drug Trikafta/Kaftrio is practically printing money, raking in a whopping $8.9 billion last year. Sure, things slowed a bit in 2023, but hey, that's still serious cash.

But here's the thing: If Vertex was just about cystic fibrosis, the price tag could make a careful investor go "Whoa, Nelly!"  Growth investors, though, see a bigger picture, a company ready to branch out and rake in even more dough.

Take the recent FDA approval for Casgevy, the gene therapy treatment Vertex developed with CRISPR Therapeutics (CRSP). This thing could be HUGE for treating blood disorders like sickle cell disease. In fact, its potential peak sales are projected at $3.9 billion — and even with Vertex splitting the profits, that's a juicy opportunity.

Another potential blockbuster is Vertex's non-opioid painkiller, VX-548. The results so far are looking good, and it’s pegged to become a $5 billion moneymaker. Think about the opioid mess we're in – a safe, effective alternative could be massive.

We need to be patient with VX-548 though. It's not approved yet, but it's definitely one to watch. Vertex is aiming to file for approval around the middle of this year, specifically for treating those nasty post-surgery pains.

Aside from these, Vertex is setting its sights on other serious unmet needs. Take APOL1-mediated kidney disease. This nasty condition lurks in the shadows until BAM, your kidneys are about to bail on you. Signs like protein in your urine and swelling mean it might be too late.

But, Vertex has a potential solution up its sleeve: inaxaplin. Early trials look promising, with patients seeing major improvement. The results were so good that they're even going to start testing it in younger patients.

Could inaxaplin be another game-changer? Well, Vertex thinks it could help at least 100,000 patients in the US and Europe – that's even more than the number of people with CF they already serve.

And, get this: There's NO approved treatment for the root cause of this kidney disease. If Vertex wins this race, it could turn into a blockbuster franchise to rival its lucrative CF success.

On top of these candidates, Vertex recently scooped up Alpine Immune Sciences (ALPN), and that move shows just how serious they are at adding more firepower to their pipeline. And, if Alpine's drug makes it through those big Phase 3 trials – the ones set to start soon – Vertex could end up being worth a LOT more than the $4.9 billion they shelled out.

For context, let's break down what Alpine does. They're all about those fancy protein-based immunotherapies, fancy words for treatments that target the immune system for autoimmune and inflammatory diseases. While their drugs are still in the testing phase, one called povetacicept looks especially promising for autoimmune kidney diseases like IgA nephropathy.

Translation: Alpine's got some traction towards treating these nasty kidney diseases. They've finished Phase 2 trials and are gearing up for the big leagues: Phase 3. That's where they test the drug on a whole bunch of patients, comparing it to a placebo, to get the data that could make regulators give the thumbs up for market launch.

With all these in mind, let’s talk about the elephant in the room: Is Vertex overpriced?

The stock's been on a tear, rocketing up 90% in just three years. And at those hefty multiples – 29 times earnings, 11 times revenue – it sure doesn't look cheap.

But, if you believe in the promise of Vertex's future, things look a little different. Check out that PEG ratio – a measly 0.5. That's a bargain hunter's dream, especially for a stock with so much growth potential.

So, what should you do: buy, sell, or hold Vertex? Well, this stock's got growth potential and it's not so insanely expensive that you gotta dump it today. If you already own it, hang tight – it doesn't look like disaster's lurking around the corner.

The bigger question is for those of you who missed the boat. Is it worth jumping on now?

As long as you're in it for the long haul, Vertex could still make you a nice pile of cash. Keep an eye on those VX-548 regulatory filings – if Vertex is moving ahead, they're probably feeling good about the drug's chances. And with Casgevy getting the green light for multiple uses, Vertex already has a shiny new revenue stream alongside its cystic fibrosis powerhouse.

So while the stock price might make you wince, don't discount the long-term potential. This biotech bull might take a breather every now and then, but the race has just begun. I suggest you buy the dip.

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-04-16 12:00:002024-04-16 11:26:34Is This Biotech Bull Run Out Of Steam?
april@madhedgefundtrader.com

Trade Alert - (TSLA) April 16, 2024 - STOP LOSS - SELL

Mad Hedge AI, Trade Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-04-16 10:05:062024-04-16 10:05:06Trade Alert - (TSLA) April 16, 2024 - STOP LOSS - SELL
april@madhedgefundtrader.com

April 16, 2024

Diary, Newsletter, Summary

Global Market Comments
April 16, 2024
Fiat Lux

Featured Trade:

(MAY 3, 2024 QUITO, ECUADOR STRATEGY LUNCHEON)
(BIDDING FOR THE STARS)
(SPX), (INDU)
(TESTIMONIAL)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-04-16 09:08:312024-04-16 10:04:30April 16, 2024
Mad Hedge Fund Trader

SOLD OUT - May 3, 2024 Quito, Ecuador Strategy Luncheon

Diary, Lunch, Newsletter

 

Come join me for lunch for my Global Strategy Luncheon, which I will be conducting in Quito Ecuador at 12:00 PM on Friday, May 3, 2024. A three-course lunch is included.

I’ll be giving you my up-to-date view on stocks, bonds, currencies commodities, precious metals, and real estate.

And to keep you in suspense, I’ll be throwing a few surprises out there too. Enough charts, tables, graphs, and statistics will be thrown at you to keep your ears ringing for a week. Tickets are available for $269.

Quito, the capital of Ecuador, is high in South America’s Andes mountains at 8,000 feet and dead on the equator. The Old Town was built by the Conquistadors on the ruins of an Inca city. It has since become a key stopover for illegal immigrants from China. Those with heart conditions should not attend.

I’ll be arriving early and leaving late in case anyone wants to have a one-on-one discussion, or just sit around and chew the fat about the financial markets.

The lunch will be held at an exclusive hotel in Quito’s Old Town, the details of which will be emailed to you.

I look forward to meeting you, and thank you for supporting my research.

To purchase tickets for this luncheon, please click here.

 

 

https://www.madhedgefundtrader.com/wp-content/uploads/2024/04/quitoecuador.png 424 918 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2024-04-16 09:06:592024-07-03 13:26:38SOLD OUT - May 3, 2024 Quito, Ecuador Strategy Luncheon
april@madhedgefundtrader.com

Bidding for the Stars

Diary, Newsletter

Risk assets everywhere are now facing a good news glut.

My 2024 market top target of 6,000 for the Dow S&P 500 is rushing ever forward with reckless abandon.

Today’s price action really gives you the feeling that we have just seen a short-term blow-off market top.

The stock market is turning into the Bitcoin market.

A few years ago, I went to a charity fundraiser at San Francisco’s priciest jewelry store, Shreve & Co., where the well-heeled men bid for dates with the local high society beauties, dripping in diamonds and their mother’s Channel No. 5.

Amply fueled with champagne, I jumped into a spirited bidding war over one of the Bay Area’s premier hotties who shall remain nameless. Suffice it to say, she is now married to a tech titan and has a sports stadium named after her.

Obviously, I didn’t work hard enough.

The bids soared to $37,000, $38,000, and $39,000.

After all, it was for a good cause. But when it hit $40,000, I suddenly developed a severe case of lockjaw. Later, the sheepish winner with a severe case of buyer’s remorse came to me and offered his date back to me for only $37,000.  I said “No thanks.” $36,000, $35,000, $34,000?

I passed.

The altitude of the stock market right now reminds me of that evening.

If you rode the S&P 500 (SPX) from 700 to 5,200 and the Dow Average (INDU) from 6,000 to 39,000, why sweat trying to eke out a few more basis points, especially when the risk/reward ratio sucks so badly, as it does now?

I realize that many of you are not hedge fund managers and that running a prop desk, mutual fund, 401k, pension fund, or day trading account has its own demands.

But let me quote what my favorite Chinese general, Deng Xiaoping, once told me in person: “There is a time to fish and a time to hang your nets out to dry.” If you followed my Trade Alerts this year and are now up 15%, you don’t have to chase every trade.

At least then I’ll have plenty of dry powder for when the window of opportunity reopens for business. So while I’m mending my nets, I’ll be building new lists of trades for you to strap on when the sun, moon, and stars align once again.

 

https://www.madhedgefundtrader.com/wp-content/uploads/2024/04/fish-net.png 480 712 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-04-16 09:04:282024-04-16 10:03:34Bidding for the Stars
april@madhedgefundtrader.com

Testimonial

Diary, Newsletter, Testimonials

In my wealth management practice, you helped me finesse last October like a virtuoso.  As my client’s investments were crashing through their stops…I hung on.  Your sage counsel helped me ignore the noise, focus on the numbers and add to positions at a great entry point.  The scar tissue you’ve built up over your career is no small benefit to your subscribers.

Thank you so much!

Brad
Bakersfield, California

 

https://www.madhedgefundtrader.com/wp-content/uploads/2024/04/john-thomas-old-car.png 560 728 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-04-16 09:02:552024-04-16 10:03:22Testimonial
Page 8 of 16«‹678910›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Scroll to top